The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Both biotech stocks could be the breakout growth story in 2026. The post These 2 ASX healthcare shares could jump well over ...

Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

Stock Market Today: The Nasdaq ends a losing streak, but barely. Small caps close flat after a choppy action.

The research, published in the journal Science Advances, details a structurally novel vaccine design where an HPV antigen and a powerful immune-stimulating adjuvant are co-engineered onto a single SNA ...

"It's not a matter of solvability," David Walsey says of his organization's battle against Lyme disease. "It's a matter of ...

The company expects to expand global distributor agreements to cover over 40 countries in 2026 and to finalize VYJUVEK pricing and launch in Italy in the second half of 2026. Management reaffirmed ...

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological ...

Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of ...

Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1 ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… ...